BOSTON– enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage non-viral genetic medicine company, announced today that Hussein Sweiti, M.D., MSc, has been appointed Chief Medical Officer, effective September 29, 2025.
Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience in clinical practice, oncology research, global drug development, regulatory submissions, and medical affairs. He most recently served as Global Medical Head of Oncology Clinical Development at Johnson & Johnson, where he led the company’s bladder cancer portfolio and played a key role in securing U.S. Food and Drug Administration approval for a treatment in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) earlier this month.
“After reaching target enrollment in detalimogene’s pivotal NMIBC clinical trial, Hussein is exactly the right fit for enGene as we transition our focus to regulatory filing and commercialization,” said Ron Cooper, Chief Executive Officer of enGene. “We’re thrilled to welcome a leader with recent filing success in this space, deep knowledge of urologic oncology and bladder cancer trials, and strong credibility across the urology community.”
“Joining enGene at this moment is energizing, as the non-viral DDX platform is unique and the science is compelling,” said Dr. Sweiti. “Urologists who treat NMIBC are looking for new options that have a unique mode of action. Detalimogene has the potential to fulfill a major clinical and physician practice need.”
At enGene, Dr. Sweiti will lead global clinical development strategy for detalimogene, the company’s investigational therapy for NMIBC, as well as future development programs. His appointment strengthens enGene’s clinical and regulatory capabilities as it prepares for a planned Biologics License Application submission for detalimogene in the second half of 2026.
Dr. Sweiti earned his medical degree from the University of Heidelberg and a Master of Science in Public Health from the University of Düsseldorf. He is board certified in surgical oncology, holds a Certification in Medical Oncology from the European Society for Medical Oncology, and has authored more than 70 peer-reviewed publications.
